![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H15N5 |
Molar mass | 193.254 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials[2] and was subsequently discontinued.
AChE inhibitor medications | |
---|---|
Other medications | |
Experimental BACE inhibitors |